AbCellera Biologics (ABCL) Shares Outstanding (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Shares Outstanding (Entity) data on file, last reported at $303.9 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 1.87% year-over-year to $303.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $303.9 million (up 1.87% YoY) and the FY2025 annual result came in at $300.6 million, up 1.64% from the prior year.
• Shares Outstanding (Entity) improved to $303.9 million in Q1 2026, from $300.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $303.9 million in Q1 2026 to a low of $284.5 million in Q1 2022.
• A 5-year average of $293.0 million and a median of $293.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The widest YoY moves for Shares Outstanding (Entity): up 5.02% in 2022, down 1.27% in 2022.
• Tracing ABCL's Shares Outstanding (Entity) over 5 years: stood at $286.9 million in 2022, then climbed by 1.39% to $290.8 million in 2023, then increased by 1.7% to $295.8 million in 2024, then gained by 1.64% to $300.6 million in 2025, then advanced by 1.11% to $303.9 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $303.9 million (Q1 2026), $300.6 million (Q4 2025), and $299.0 million (Q3 2025), per Business Quant data.